Chronic itch: emerging treatments following new research concepts
L. Misery, E. Brenaut, Ophélie Pierre, Raphaële Le Garrec, Olivier Gouin, Nicolas Lebonvallet, C. Abasq‐Thomas, Matthieu Talagas, C. Le Gall‐Ianotto, Catherine Besner Morin, Joachim W. Fluhr, Cyril Leven
Abstract
Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL‐31, IL‐4/13, NK 1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas‐related GPCRs and unexpected new pathways need to be also explored.
Topics & Concepts
MedicineNeuroscienceSignalling pathwaysG protein-coupled receptorBioinformaticsReceptorPharmacologyBiologyInternal medicineDermatology and Skin DiseasesUrticaria and Related ConditionsAllergic Rhinitis and Sensitization